chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 15.0
Sex: F
Vaccine: HPV4
Symptoms: Nervous system disorder, Peripheral coldness, Seizure, Syncope
Clinical narrative: seizures,short of breath; Autonomic nervous system imbalance; celiac disease, joint pain,autoinmmune disorder; Depression; cold hands; she passed out; First dose 06-JUN-2019, second dose 10-JUL-2020, third dose 13-NOV-2020.; Crohn's disease,changes in her bowel habits, fatigue and difficultywith stamina,autoinmmune disorder/, chronic diarrhea; acne; heavy bleeding during/menstruation; Information has been received from a lawyer regarding a case in litigation, concerning an adult female patient (pt) of unknown age. The pt's medical history, concurrent conditions, and concomitant medications were not provided. On 06-JUN-2019 (when she was 15 years old), the pt was vaccinated with the first dose of Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) intramuscular injection as prevention of cervical cancer (dose, route of administration, anatomical location, lot number, and expiration date were not provided). Also, on 10-JUL-2020 (Inappropriate schedule of product administration) and 13-NOV-2020, she received the second and third dose respectively of Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) (dose, route of administration, anatomical location, lot number, and expiration date were not provided). On 10-JUL-2020, right after the second vaccination, the patient passed out (loss of consciousness). On an unknown date in 2020, following the second vaccination, the pt developed chronic fatigue, had difficulty with stamina. She began having severe acne and changes in her bowel habits. She had, also heavy bleeding during menstruation, it was stated that she sought treatment with multiple physicians, but her health continued to worsen. Then, on an unknown date, after the third vaccination, her health declined further, including severe depression, chronic diarrhea, cold hands when the rest of her body is hot, fainting/seizures, short of breath, and joint pain, the pt sought again for unspecified treatment with multiple physicians and specialists and was eventually diagnosed with celiac disease and Crohn's disease and Gardasil-induced autoimmune, autonomic, and neurological diseases. The outcome of aforementioned events was not provided. It were considered the events was related to Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL).   Upon internal review, the events Crohn's disease, Coeliac disease, Loss of consciousness and Seizure considered were determined to be a medically significant.
Age: 85.0
Sex: M
Vaccine: COVID19, COVID19-2, PNC13, RSV
Symptoms: CSF test abnormal, Cognitive disorder, Dysphagia, Dyspnoea, Fall
Clinical narrative: Three days after receiving Covid-19 vaccine patient started getting weakness in legs and began falling many times.  As time progressed he became mentally confused and started hallucinating.  Was seen in ER on December 28, 2023 and returned on January 1, 2024.  Was admitted to hospital on January 1, 2024.  MRI and Spinal tap were done.  He was started on an antibiotic without any improvement.  On Saturday, January 6, 2024 while visiting at hospital Dr informed his wife and other people that patient was suffering from Guillain-Barre syndrome.  This was discovered after a consultation with a Dr at hospital.  IVIG Infusion therapy was started. (Continued)In addition to the generalized weakness and falling at the start of the illness patient became incontinent and was having trouble with speech. He lost sense of taste and smell.  As the illness progressed he lost feeling in his feet then legs.  His arms were very weak.   On January 11, 2024 patient was transferred.  He was too weak to start any type of therapy at the Hospital rehabiliation center. As of January 19, 2024 he remains in hospital and is making very slow progress.
Age: 85.0
Sex: M
Vaccine: COVID19, COVID19-2, PNC13, RSV
Symptoms: Guillain-Barre syndrome, Hypoaesthesia, Imaging procedure, Immunoglobulin therapy, Mental status changes
Clinical narrative: Three days after receiving Covid-19 vaccine patient started getting weakness in legs and began falling many times.  As time progressed he became mentally confused and started hallucinating.  Was seen in ER on December 28, 2023 and returned on January 1, 2024.  Was admitted to hospital on January 1, 2024.  MRI and Spinal tap were done.  He was started on an antibiotic without any improvement.  On Saturday, January 6, 2024 while visiting at hospital Dr informed his wife and other people that patient was suffering from Guillain-Barre syndrome.  This was discovered after a consultation with a Dr at hospital.  IVIG Infusion therapy was started. (Continued)In addition to the generalized weakness and falling at the start of the illness patient became incontinent and was having trouble with speech. He lost sense of taste and smell.  As the illness progressed he lost feeling in his feet then legs.  His arms were very weak.   On January 11, 2024 patient was transferred.  He was too weak to start any type of therapy at the Hospital rehabiliation center. As of January 19, 2024 he remains in hospital and is making very slow progress.
Age: 85.0
Sex: M
Vaccine: COVID19, COVID19-2, PNC13, RSV
Symptoms: Muscular weakness, Peripheral sensory neuropathy, Sensory loss
Clinical narrative: Three days after receiving Covid-19 vaccine patient started getting weakness in legs and began falling many times.  As time progressed he became mentally confused and started hallucinating.  Was seen in ER on December 28, 2023 and returned on January 1, 2024.  Was admitted to hospital on January 1, 2024.  MRI and Spinal tap were done.  He was started on an antibiotic without any improvement.  On Saturday, January 6, 2024 while visiting at hospital Dr informed his wife and other people that patient was suffering from Guillain-Barre syndrome.  This was discovered after a consultation with a Dr at hospital.  IVIG Infusion therapy was started. (Continued)In addition to the generalized weakness and falling at the start of the illness patient became incontinent and was having trouble with speech. He lost sense of taste and smell.  As the illness progressed he lost feeling in his feet then legs.  His arms were very weak.   On January 11, 2024 patient was transferred.  He was too weak to start any type of therapy at the Hospital rehabiliation center. As of January 19, 2024 he remains in hospital and is making very slow progress.
Age: 85.0
Sex: M
Vaccine: COVID19, COVID19-2, PNC13, RSV
Symptoms: Ageusia, Anosmia, Asthenia, Confusional state, Dysarthria
Clinical narrative: Three days after receiving Covid-19 vaccine patient started getting weakness in legs and began falling many times.  As time progressed he became mentally confused and started hallucinating.  Was seen in ER on December 28, 2023 and returned on January 1, 2024.  Was admitted to hospital on January 1, 2024.  MRI and Spinal tap were done.  He was started on an antibiotic without any improvement.  On Saturday, January 6, 2024 while visiting at hospital Dr informed his wife and other people that patient was suffering from Guillain-Barre syndrome.  This was discovered after a consultation with a Dr at hospital.  IVIG Infusion therapy was started. (Continued)In addition to the generalized weakness and falling at the start of the illness patient became incontinent and was having trouble with speech. He lost sense of taste and smell.  As the illness progressed he lost feeling in his feet then legs.  His arms were very weak.   On January 11, 2024 patient was transferred.  He was too weak to start any type of therapy at the Hospital rehabiliation center. As of January 19, 2024 he remains in hospital and is making very slow progress.
Age: 85.0
Sex: M
Vaccine: COVID19, COVID19-2, PNC13, RSV
Symptoms: Fall, Guillain-Barre syndrome, Hallucination, Hypoaesthesia, Immunoglobulin therapy
Clinical narrative: Three days after receiving Covid-19 vaccine patient started getting weakness in legs and began falling many times.  As time progressed he became mentally confused and started hallucinating.  Was seen in ER on December 28, 2023 and returned on January 1, 2024.  Was admitted to hospital on January 1, 2024.  MRI and Spinal tap were done.  He was started on an antibiotic without any improvement.  On Saturday, January 6, 2024 while visiting at hospital Dr informed his wife and other people that patient was suffering from Guillain-Barre syndrome.  This was discovered after a consultation with a Dr at hospital.  IVIG Infusion therapy was started. (Continued)In addition to the generalized weakness and falling at the start of the illness patient became incontinent and was having trouble with speech. He lost sense of taste and smell.  As the illness progressed he lost feeling in his feet then legs.  His arms were very weak.   On January 11, 2024 patient was transferred.  He was too weak to start any type of therapy at the Hospital rehabiliation center. As of January 19, 2024 he remains in hospital and is making very slow progress.
Age: 85.0
Sex: M
Vaccine: COVID19, COVID19-2, PNC13, RSV
Symptoms: Incontinence, Lumbar puncture, Magnetic resonance imaging, Muscular weakness
Clinical narrative: Three days after receiving Covid-19 vaccine patient started getting weakness in legs and began falling many times.  As time progressed he became mentally confused and started hallucinating.  Was seen in ER on December 28, 2023 and returned on January 1, 2024.  Was admitted to hospital on January 1, 2024.  MRI and Spinal tap were done.  He was started on an antibiotic without any improvement.  On Saturday, January 6, 2024 while visiting at hospital Dr informed his wife and other people that patient was suffering from Guillain-Barre syndrome.  This was discovered after a consultation with a Dr at hospital.  IVIG Infusion therapy was started. (Continued)In addition to the generalized weakness and falling at the start of the illness patient became incontinent and was having trouble with speech. He lost sense of taste and smell.  As the illness progressed he lost feeling in his feet then legs.  His arms were very weak.   On January 11, 2024 patient was transferred.  He was too weak to start any type of therapy at the Hospital rehabiliation center. As of January 19, 2024 he remains in hospital and is making very slow progress.
Sex: M
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: pneumonia; Information has been received from Health Authority on 12-JAN-2024.   This spontaneous report was received from Regulatory Authority and refers to a 50-54-year-old male patient (exact age was not provided). Information regarding the patient's concurrent conditions, medical history, and concomitant medications was not provided.   On an unknown date, the patient was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine (manufacturer unknown) (exact dose, frequency, route of administration, anatomical location, lot number and expiration date were not reported) for prophylaxis.  On an unknown date in 2020, the patient experienced Streptococcus pneumoniae pneumonia, and Streptococcus pneumoniae serotyping result was reported as not available. The outcome of the event was not reported.   The relatedness between the event and the suspect vaccines was not provided.   Upon internal review, the event of Streptococcus pneumoniae pneumonia was determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: Pneumonia; Information has been received from Regulatory Authority on 12-JAN-2024.  This spontaneous report received from public data set 2009 to 2022 (data current as at 29-JUN-2023) about invasive pneumococcal disease (streptococcus pneumoniae) of Diseases Surveillance System (DSS) and referred to a larger than 85 years old female patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, administered for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided).   In 2009, the patient experienced streptococcus pneumoniae pneumonia, serotype was Not Available. The outcome of the event was not reported.   The causal relationship between the event and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not reported.  Upon internal review, the event streptococcus pneumoniae pneumonia was determined to be medically significant.
Sex: F
Vaccine: PNC, PPV
Symptoms: Pneumococcal bacteraemia, Streptococcus test
Clinical narrative: Bacteraemia; Information has been received from Health Authority (Agency number not provided) on 12-JAN-2024.  This spontaneous report was received from National Notifiable Diseases Surveillance System (NNDSS) and refers to a 10-14 years old female patient (exact age was not provided). Information regarding the patient's concurrent conditions, medical history, and concomitant medications was not provided.  On an unknown date, the patient was vaccinated with a first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) (exact dose, frequency, route of administration, anatomical location, lot number and expiration date were not reported) for prophylaxis.   On unknown dates, the patient was also vaccinated with 3 doses of pneumococcal vaccine conj 7V (CRM197) (PREVENAR) (exact doses, frequencies, routes of administration, anatomical locations, lot numbers and expiration dates were not reported) for prophylaxis.   On an unknown date in 2012, the patient experienced pneumococcal bacteraemia, and streptococcus pneumoniae serotyping result was not available. The outcome of the event was not reported.  The relatedness between the event and the suspect vaccines was not provided.  Upon internal review, the event of pneumococcal bacteraemia was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: Pneumonia; Information has been received from Agency on 12-JAN-2024.  This spontaneous report has been downloaded from Regulatory Authority and referring to an Adult male patient (age: 35-39 years old).  The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, 1 time, for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided).  On an unknown date in 2009, the patient experienced streptococcus pneumoniae pneumonia. On an unknown date in 2009, streptococcus pneumoniae serotyping showed Not available. At the time of reporting, the outcome of the event was not known.   The causal relationship between the event and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was unknown.  Upon internal review, the event of streptococcus pneumoniae pneumonia was determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: Pneumonia; Information has been received from a Health Authority on 12-JAN-2024.  This spontaneous report as received from a Diseases Surveillance System (DSS) refers to a female adult patient of unknown exact age (age group reported as '50-54'). No information regarding the patient's medical history, concurrent conditions and concomitant medications was provided.  On unknown day, the patient was vaccinated with a first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX 23) (dose, route of administration, anatomical location, lot number and expiration date were not reported) for prophylaxis.   On an unknown date in 2013, the patient experienced pneumococcal pneumonia. Streptococcus pneumoniae serotyping was not available. The outcome of the event was not reported.        The relatedness between pneumococcal pneumonia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX 23) was not provided.  Upon internal review, the event of pneumococcal pneumonia was determined to be medically significant.
Sex: M
Vaccine: PNC, PPV
Symptoms: Pneumococcal bacteraemia
Clinical narrative: Bacteraemia; Information has been received from Health Authority (no agency number) on 12-JAN-2024.  This spontaneous report was received from National Notifiable Diseases Surveillance System (NNDSS) and refers to a male patient of unknown age (reported as 10-14). There was no information about the patient's concurrent conditions, concomitant therapies, or medical history provided.  On an unknown dates, the patient was vaccinated with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection; and pneumococcal vaccine conj 7v (crm197) (PREVENAR), 2 times in total, both administered for prophylaxis (strengths, doses, anatomical locations, lot numbers, expiry dates, and routes of administration were not provided).  On an unknown date in 2012, the patient experienced Pneumococcal bacteraemia. On an unknown date in 2012, Streptococcus pneumoniae serotyping was not available. The outcome of the event was not known. The action taken with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) regarding the event was assessed as Not Applicable.  The causal relationship between the event and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not reported.  Upon internal review, the event of Pneumococcal bacteraemia was determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: pneumonia; Information has been received from {HA} (agency number was not provided) on 12-JAN-2024 and refers to female patient of unknown exact age (age group reported as: 40-44, adult). The patient's medical history, concurrent conditions and concomitant therapies were not provided.  On an unknown date, the patient was vaccinated with the first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23), formulation: injection (lot #, expiration date, exact dose, route of administration and anatomical location were not reported) for prophylaxis. On an unknown date, the patient was vaccinated with the second dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23), formulation: injection (lot #, expiration date, exact dose, route of administration and anatomical location were not reported) for prophylaxis.  On unknown date in 2012, the patient experienced pneumonia pneumococcal. The Streptococcus pneumoniae serotyping was performed but the result was not available. The outcome of pneumonia pneumococcal was unknown.  The relatedness between the event of pneumonia pneumococcal and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not reported.   The event of pneumonia pneumococcal was considered to be medically significant according to HA.
Sex: F
Vaccine: PPV
Symptoms: Pneumonia pneumococcal, Streptococcus test positive
Clinical narrative: Pnuemonia; Information has been received from a Health Authority on 12-JAN-2024.  This spontaneous report as received from a Regulatory Authority refers to a child female patient of unknown age (age group reported as 5-9). No information regarding the patient's medical history, concurrent conditions and concomitant medications was provided.  On an unknown dates, the patient was vaccinated with the first, second and third doses of pneumococcal 23v polysaccharide vaccine (manufacturer unknown) injection, administered for prophylaxis (dose, route of administration, anatomical location, lot number and expiration date were not reported).  On an unknown date in 2018, the patient experienced pneumonia (Pneumonia pneumococcal). On an unknown date in 2018, Streptococcus pneumoniae serotype result was not available. The outcome of the event was not reported.  The causal relationship between the event and pneumococcal 23v polysaccharide vaccine (manufacturer unknown) was not reported.  Upon internal review, the event was determined to be medically significant event.
Sex: M
Vaccine: PPV
Symptoms: Pneumococcal infection
Clinical narrative: Other; Information has been received from Health Authority on 12-JAN-2024.  This spontaneous report was received from Authority Surveillance System (SS) and refers to a male adult patient (age: 25-29). The patient's medical history, historical drugs, concurrent conditions, and concomitant drugs were not reported.  On unknown dates, the patient was vaccinated with two doses of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX 23) injection (strength, dose, route of administration, lot#, and expiration date were not reported) for prophylaxis.  On an unknown date in 2013, the patient experienced pneumococcal infection (Streptococcus pneumoniae serotyping not available). The outcome of the event was not reported.  The causal relationship between the event and suspect vaccine was not provided.  Upon internal review, the event of pneumococcal infection was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: pneumonia; Information has been received from a Health Authority on 12-JAN-2024.  This spontaneous report as received from a Health Authority refers to an elderly male patient of unknown exact age (age group reported as 85+ years old). No information regarding the patient's medical history, concurrent conditions and concomitant medications was provided.  On an unknown date, the patient was vaccinated with a first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) (dose, route of administration, anatomical location, lot number and expiration date were not reported) for prophylaxis.  On an unknown date in 2012, the patient experienced Streptococcus pneumoniae pneumonia. Streptococcus pneumoniae serotyping was not available. The outcome of the event was not reported.   The relatedness between Streptococcus pneumoniae pneumonia and the suspect vaccine was not provided.  Upon internal review, the event of pneumococcal infection was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: Pneumonia; Information has been received from HA on 12-JAN-2024.  This spontaneous report has been downloaded from Regulatory Authority and refers to a male patient (55-59). His medical history, concurrent conditions and concomitant therapies were not provided.  On an unknown date, the patient was vaccinated with first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, administered for prophylaxis (anatomical location, strength, lot #, expiry date, and route of administration were not provided).  On an unknown date in 2013, the patient experienced pneumonia (Pneumonia pneumococcal). Streptococcus pneumoniae serotyping was not available. At the time of reporting, the outcome of the event was not known.  The causal relationship between the event and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not reported.  Upon internal review, the event of pneumonia (Pneumonia pneumococcal) was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumococcal infection, Pneumonia pneumococcal
Clinical narrative: Other; Pneumonia; Information has been received from a Health Authority on 12-JAN-2024.  This spontaneous report as received from a Diseases Surveillance System (DSS) refers to an adult male patient of unknown age (age group reported as 45-49). No information regarding the patient's medical history, concurrent conditions, and concomitant medications was provided.  On unknown dates, the patient was vaccinated with two doses of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, administered for prophylaxis (dose, route of administration, anatomical location, lot number and expiration date were not reported).  On an unknown date in 2015, the patient experienced Streptococcus pneumoniae pneumonia and unspecified Pneumococcal infection (reported as "Other"). On an unknown date in 2015, Streptococcus pneumoniae serotyping was not available. The outcome of the event was not reported.  The causal relationship between the events and suspected vaccine was not reported.  Upon internal review, the event of Streptococcus pneumoniae pneumonia and unspecified Pneumococcal infection were determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Pneumococcal infection
Clinical narrative: Other; Information has been received from Health Authority on 12-JAN-2024.  This spontaneous report was received and refers to a 40-44-year-old female patient (exact age was not provided). Information regarding the patient's concurrent conditions, medical history, and concomitant medications was not provided.  On unspecified days, the patient was vaccinated with the first and the second dose (total vaccinations number was reported as 2) of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) (exact doses, frequencies, routes of administration, anatomical locations, lot numbers and expiration dates were not reported) for prophylaxis.  On an unknown date in 2013, the patient experienced Pneumococcal infection (reported as Other), and Streptococcus pneumoniae serotyping result was reported as not available. The outcome of the event was not reported.   The relatedness between the event and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not provided.   Upon internal review, the event of Pneumococcal infection was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: Pneumonia; Information has been received from a Health Authority on 12-JAN-2024.  This spontaneous report as received refers to an elderly male patient of unknown age (age group reported as 70-74). No information regarding the patient's medical history, concurrent conditions, and concomitant medications was provided.  On an unknown date, the patient was vaccinated with one dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, administered for prophylaxis (dose, route of administration, anatomical location, lot number and expiration date were not reported).  On an unknown date in 2012, the patient experienced Streptococcus pneumoniae pneumonia. On an unknown date in 2012, Streptococcus pneumoniae serotyping was not available. The outcome of the event was not reported.  The causal relationship between the event and suspected vaccine was not reported.  Upon internal review, the event of Streptococcus pneumoniae pneumonia was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumococcal infection
Clinical narrative: Other; Information has been received from Health Authority on 12-JAN-2024.   This spontaneous report was received and refers to a 40-44-year-old male patient (exact age was not provided). Information regarding the patient's concurrent conditions, medical history, and concomitant medications was not provided.   On unspecified day, the patient was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) (exact dose, frequency, route of administration, anatomical location, lot number and expiration date were not reported) for prophylaxis.  On an unknown date in 2013, the patient experienced Pneumococcal infection (reported as Other), and Streptococcus pneumoniae serotyping result was reported as not available. The outcome of the event was not reported.   The relatedness between the event and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not provided.   Upon internal review, the event of Pneumococcal infection was determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Meningitis pneumococcal, Streptococcus test
Clinical narrative: Meningitis; Information has been received from {RA} Regulatory Authority (agency number was not provided) on 12-JAN-2024 and refers to female patient of unknown exact age (age group reported as: 35-39, adult). The patient's medical history, concurrent conditions and concomitant therapies were not provided.  On an unknown date, the patient was vaccinated with the first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23), formulation: injection (lot #, expiration date, exact dose, route of administration and anatomical location were not reported) for prophylaxis.   On unknown date in 2013, the patient experienced meningitis pneumococcal. The Streptococcus pneumoniae serotyping was performed but the result was not available. The outcome of meningitis pneumococcal was unknown.  The relatedness between the event of meningitis pneumococcal and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not reported.   The event of meningitis pneumococcal was considered to be medically significant according to ASTL.
Sex: M
Vaccine: PPV
Symptoms: Pneumococcal infection, Streptococcus test
Clinical narrative: Other; Information has been received from {HA} (SS) (agency number was not provided) on 12-JAN-2024 and refers to male patient of unknown exact age (age group reported as: 35-39, adult). The patient's medical history, concurrent conditions and concomitant therapies were not provided.  On an unknown date, the patient was vaccinated with the first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23), formulation: injection (lot #, expiration date, exact dose, route of administration and anatomical location were not reported) for prophylaxis.  On unknown date in 2013, the patient experienced pneumococcal infection. The Streptococcus pneumoniae serotyping was performed but the result was not available. The outcome of pneumococcal infection was unknown.  The relatedness between the event of pneumococcal infection and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not reported.   The event of pneumococcal infection was considered to be medically significant according to Agency.
Sex: F
Vaccine: PPV
Symptoms: Pneumococcal infection
Clinical narrative: other; Information has been received from a Health Authority on 12-JAN-2024.  This spontaneous report as received from a Health Authority refers to an adult female patient of unknown age (age group reported as 60-64). No information regarding the patient's medical history, concurrent conditions, and concomitant medications was provided.  On an unknown date, the patient was vaccinated with one dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, administered for prophylaxis (dose, route of administration, anatomical location, lot number and expiration date were not reported).  On an unknown date in 2013, the patient experienced unspecified Pneumococcal infection (reported as "other"). On an unknown date in 2013, Streptococcus pneumoniae serotyping was not available. The outcome of the event was not reported.  The causal relationship between the event and suspected vaccine was not reported.  Upon internal review, the event of unspecified Pneumococcal infection was determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: Pneumonia; Information has been received from Health Authority on 12-JAN-2024.   This spontaneous report was received from National Notifiable Diseases Surveillance System (NNDSS) and refers to a 60-64-year-old female patient (exact age was not provided). Information regarding the patient's concurrent conditions, medical history, and concomitant medications was not provided.   On unspecified day, the patient was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) (exact dose, frequency, route of administration, anatomical location, lot number and expiration date were not reported) for prophylaxis.  On an unknown date in 2013, the patient experienced Streptococcus pneumoniae pneumonia, and Streptococcus pneumoniae serotyping result was reported as not available. The outcome of the event was not reported.   The relatedness between the event and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not provided.   Upon internal review, the event of Streptococcus pneumoniae pneumonia was determined to be medically significant.
Sex: F
Vaccine: PNC, PPV
Symptoms: Pneumonia, Streptococcus test
Clinical narrative: Pneumonia; Information has been received from Health Authority on 12-JAN-2024.  This spontaneous report has been downloaded from National Notifiable Diseases Surveillance System (NNDSS) and refers to a child (between 5 and 9 years old; reported as age group 05-09) female patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, administered for prophylaxis (exact dose, strength, lot #, expiry date, and route of administration were not provided). On an unknown dates, the patient received 2 doses of and pneumococcal vaccine conj 7v (crm197) (PREVENAR), administered for prophylaxis (exact dose, strength, formulation, lot #, expiry date, and route of administration were not provided). It was reported that the patient received total of 3 vaccinations.  In 2015, the patient experienced pneumonia, serotype: not available. The outcome of the event was not provided.   The causal relationship between pneumonia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not reported.  Upon internal review, the event of pneumonia has been determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Pneumococcal infection
Clinical narrative: No data provided; Information has been received from Regulatory Agency on 12-JAN-2024.  This spontaneous report has been downloaded from Surveillance System referring to an elderly female patient (age: 75-79 years old). The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On unknown date, the patient was vaccinated with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, 1 time, as prophylaxis (strength, dose, lot#, expiry date, route of administration and anatomical location not reported).  On an unknown date in 2022, the patient experienced pneumococcal infection. At the time of reporting, the outcome of the event pneumococcal infection was unknown. The action taken with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not applicable.  The causal relationship between pneumococcal infection and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was unknown.  Upon internal review, the event of pneumococcal infection was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumococcal infection
Clinical narrative: Pneumococcal infection; Information has been received from HA On 12-JAN-24 (for last significant version).  This spontaneous report was referring to a male adult patient (age: 35-39). The patient's medical history, historical drugs, concurrent conditions, and concomitant drugs were not reported.  On an unknown date, the patient started therapy with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, unk, administered for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided).   On an unknown date in 2022, the patient experienced Pneumococcal infection. On an unknown date in 2022, Streptococcus pneumoniae serotyping showed Not Available. At the time of reporting, the outcome of the event  Pneumococcal infection was not known. The action taken with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) regarding Pneumococcal infection was reported as Not Applicable.   The causal relationship between Pneumococcal infection and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was unknown. Upon internal review, the event of  Pneumococcal infection  was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumococcal infection
Clinical narrative: Pneumococcal infection; Information has been received from HA (National Notifiable Diseases Surveillance System).  on 12-JAN-2024.  This spontaneous report was referring to an elderly male patient (age: 85+). The patient's medical history, concurrent conditions, and concomitant drugs were not reported.  On an unknown date, the patient was vaccinated with the first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection (strength, dose, route of administration, lot#, and expiration date were not reported) for prophylaxis.   On an unknown date in 2022, the patient experienced Pneumococcal infection. On an unknown date in 2022, streptococcus pneumoniae serotyping showed not available. Vaccine not available for Serotype. At the time of reporting, the outcome of the event Pneumococcal infection was unknown. The action taken with suspect vaccine was not applicable.  The causal relationship between the event and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not provided.  Upon internal review, the event of Pneumococcal infection was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumococcal infection
Clinical narrative: Pneumococcal infection; Information has been received from Regulatory Authority On 12-JAN-24 (for last significant version).  This spontaneous report was referring to a male adult patient (age: 40-44). The patient's medical history, historical drugs, concurrent conditions, and concomitant drugs were not reported.  On an unknown date, the patient started therapy with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, administered for prophylaxis (strength, dose,  lot #, expiry date, and route of administration were not provided).   On an unknown date in 2022, the patient experienced Pneumococcal infection. On an unknown date in 2022, Streptococcus pneumoniae serotyping showed Not available. At the time of reporting, the outcome of the event Pneumococcal infection was not known. The action taken with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) regarding Pneumococcal infection was reported as Not Applicable.    The causal relationship between Streptococcus Pneumococcal infection  and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was unknown. Upon internal review, the event of Pneumococcal infection was determined to be medically significant.
Sex: F
Vaccine: PNC, PPV
Symptoms: Pneumococcal infection
Clinical narrative: No data provided; Information has been received from RA Regulatory Authority on 12-JAN-2024.  This spontaneous report has been downloaded from Regulatory Authority referring to a female patient (15-19 years old). The patient's pertinent medical history, concurrent conditions, drugs reactions or allergies and concomitant medications were not provided.  On an unknown date, the patient was vaccinated with 1 dose (time) of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection (strength, dose, lot #, expiry date, route of administration and anatomical location were not provided) for prophylaxis. On unknown dates, the patient was vaccinated with 3 doses (times) of pneumococcal vaccine conj 7v (crm197) (PREVENAR) (strength, dose, lot #, expiry date, route of administration and anatomical location were not provided) for prophylaxis.  On an unknown date in 2022, the patient experienced pneumococcal infection. On an unknown date in 2022, streptococcus pneumoniae serotyping was not available. At the time of reporting, the outcome of the event was not reported.   The causal relationship between pneumococcal infection and suspect vaccines was not provided.  Upon internal review, the event pneumococcal infection was determined to be medically significant.
Sex: F
Vaccine: PNC13, PPV
Symptoms: Pneumococcal infection
Clinical narrative: Pneumococcal infection; Information has been received from Regulatory Agency 12-JAN-2024.  This spontaneous report has been downloaded from Regulatory Authority and referring to a female patient who is between 35-39 years old. The patient's concurrent conditions, medical history and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided) for one time. On an unknown date, she was vaccinated with pneumococcal vaccine conj 13v (crm197) (PREVENAR 13) (strength, dose, lot #, expiry date, and route of administration were not provided) for one time.  On an unknown date in 2022, the patient experienced pneumococcal infection. On an unknown date in 2022, streptococcus pneumoniae serotyping was not available. At the time of reporting, the outcome of pneumococcal infection was unknown.  The causal relationship between pneumococcal infection and both suspect vaccines was not provided.  Upon internal review, pneumococcal infection was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: Streptococcus pneumoniae pneumonia; Information has been received from Agency on 12-JAN-2024.  This spontaneous report has been downloaded from Regulatory Authority and referring to a 25-29 years old male patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, administered for prophylaxis (strength, lot #, expiry date, and route of administration were not provided). Total 1 dose was vaccinated.  On an unknown date in 2022, the patient experienced streptococcus pneumoniae pneumonia, streptococcus pneumoniae serotyping showed not available. At the time of reporting, the outcome of the event was unknown. The causal relationship between streptococcus pneumoniae pneumonia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was unknown.  Upon internal review, the event of streptococcus pneumoniae pneumonia was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: Streptococcus pneumoniae pneumonia; Information has been received from {HA} (authority number was not provided). This spontanous report was recieved from regulatory authority and refers to male patient in age grup 60-years-old to 64-years-old.  The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with one dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, unk, administered for prophylaxis (strength, lot #, expiry date, and route of administration were not provided).  On an unknown date in 2018, the patient experienced Streptococcus pneumoniae pneumonia. On an unknown date in 2018, Streptococcus pneumoniae serotyping showed not avaliable. At the time of reporting, the outcome of the event Streptococcus pneumoniae pneumonia was not known.   The causal relationship between Streptococcus pneumoniae pneumonia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was unknown. Upon internal review the event of Streptococcus pneumoniae pneumonia was estimated to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumonia
Clinical narrative: Pneumonia; Information has been received from Health Authority on 12-JAN-2024.  This spontaneous report has been downloaded from Regulatory Authority and refers to an elderly (more than 85 years old; reported as age group 85 plus) male patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, administered for prophylaxis (exact dose, strength, lot #, expiry date, and route of administration were not provided). It was reported that the patient received total of 1 vaccination.  In 2016, the patient experienced pneumonia, serotype: not available. The outcome of the event was not provided.   The causal relationship between pneumonia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not reported.  Upon internal review, the event of pneumonia has been determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumonia
Clinical narrative: Pneumonia; Information has been received from Health Authority on 12-JAN-2024.  This spontaneous report has been downloaded from Regulatory Agency and refers to an elderly (between 65 and 69 years old; reported as age group 65-69) male patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, administered for prophylaxis (exact dose, strength, lot #, expiry date, and route of administration were not provided). It was reported that the patient received total of 1 vaccination.  In 2016, the patient experienced pneumonia, serotype: not available. The outcome of the event was not provided.   The causal relationship between pneumonia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not reported.  Upon internal review, the event of pneumonia has been determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Pneumococcal infection
Clinical narrative: Clinical category: No data provided; Information has been received from Regulatory Agency on 12-JAN-2024.  This spontaneous report was referring to an elderly female patient (age: 70-74). The patient's medical history, concurrent conditions, and concomitant drugs were not reported.  On an unknown date, the patient was vaccinated with the first dose of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX 23) injection (strength, dose, route of administration, lot#, and expiration date were not reported) for prophylaxis.   On an unknown date in 2022, the patient experienced pneumococcal infection. On an unknown date in 2022, streptococcus pneumoniae serotyping showed not available. At the time of reporting, the outcome of the event pneumococcal infection was unknown.   The causal relationship between the event and pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX 23) was not provided.  Upon internal review, the event of pneumococcal infection was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumococcal infection
Clinical narrative: Clinical category: No data provided; Information has been received from Regulatory Agency on 12-JAN-2024.  This spontaneous report was referring to an elderly male patient (age: 85+). The patient's medical history, concurrent conditions, and concomitant drugs were not reported.  On an unknown date, the patient was vaccinated with the first dose of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX 23) injection (strength, dose, route of administration, lot#, and expiration date were not reported) for prophylaxis.   On an unknown date in 2022, the patient experienced pneumococcal infection. On an unknown date in 2022, streptococcus pneumoniae serotyping showed not available. At the time of reporting, the outcome of the event pneumococcal infection was unknown.   The causal relationship between the event and pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX 23) was not provided.  Upon internal review, the event of pneumococcal infection was determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: Pneumonia; Information has been received from Regulatory Authority On 12-JAN-2024.  This spontaneous report was referring to an elderly female patient (age: 80-84). The patient's medical history, concurrent conditions, and concomitant drugs were not reported.  On an unknown date, the patient was vaccinated with the first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection (strength, dose, route of administration, lot#, and expiration date were not reported) for prophylaxis. On an unknown date, the patient was vaccinated with the second dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection (strength, dose, route of administration, lot#, and expiration date were not reported) for prophylaxis.   On an unknown date in 2010, the patient experienced Pneumonia pneumococcal. On an unknown date in 2010, streptococcus pneumoniae serotyping showed not available. Vaccine not available for serotype. At the time of reporting, the outcome of the event Pneumonia pneumococcal was unknown. The action taken with suspect vaccine was not applicable.  The causal relationship between the event and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not provided.  Upon internal review, the event of Pneumonia pneumococcal was determined to be medically significant.